From the Section on Biostatistics, Bowman Gray School of Medicine of Wake
Forest University, Winston-Salem, NC (M.A.E, C.W.); the Department of
Medicine, University of Washington, Northwest Lipid Research Laboratories,
Seattle (S.M.M); George Washington University Lipid Research Clinic,
Washington, DC (V.M.); the Center for Research in Disease Prevention, Stanford
University, Palo Alto, Calif (P.D.W.); the Department of Epidemiology and
Preventive Medicine, University of Maryland School of Medicine, Baltimore
(T.L.B., R.S.); and the Lipid Research Clinic, University of Iowa, Iowa City
(H.S.).
Correspondence to Mark A. Espeland, PhD, Section on Biostatistics, Bowman Gray School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1063. E-mail mespelan{at}rc.phs.bgsm.edu
Background—Postmenopausal hormone
therapy has been reported to decrease levels of lipoprotein (Lp)(a) in
cross-sectional studies and small or short-term longitudinal studies.
We report findings from a large, prospective, placebo-controlled
clinical trial that allows a broad characterization of these effects
for four regimens of hormone therapy.
Methods and Results—The Postmenopausal Estrogen/Progestin
Interventions study was a 3-year, placebo-controlled, randomized
clinical trial to assess the effect of hormone regimens on
cardiovascular disease risk factors in postmenopausal
women 45 to 65 years of age. The active regimens were conjugated equine
estrogens therapy at 0.625 mg daily, alone or in combination with each
of three regimens of progestational agents:
medroxyprogesterone acetate (MPA) at 2.5 mg daily
(ie, continuous MPA), MPA at 10 mg days 1 to 12 (ie, cyclical MPA), and
micronized progesterone at 200 mg days 1 to 12. Plasma levels of Lp(a)
were measured at baseline (n=366), 12 months (n=354), and 36 months
(n=342). Assignment to hormone therapy resulted in a 17% to 23%
average drop in Lp(a) concentrations relative to placebo
(P<.0001), which was maintained across 3 years of
follow-up. No significant differences were observed among the four
active arms. Changes in Lp(a) associated with hormone therapy were
positively correlated with changes in LDL cholesterol,
total cholesterol, apolipoprotein B, and fibrinogen levels
and were similar across subgroups defined by age, weight, ethnicity,
and prior hormone use.
Conclusions—Postmenopausal estrogen therapy, with or without
concomitant progestin regimens, produces consistent and
sustained reductions in plasma Lp(a) concentrations.
© 1998 American Heart Association, Inc.
Clinical Investigation and Reports
Effect of Postmenopausal Hormone Therapy on Lipoprotein(a) Concentration
Key Words: lipids • lipoproteins • hormones • cardiovascular diseases • risk factors
This article has been cited by other articles:
 |
|
 |
|
  Y. Kharode, P. V. N. Bodine, C. P. Miller, C. R. Lyttle, and B. S. Komm The Pairing of a Selective Estrogen Receptor Modulator, Bazedoxifene, with Conjugated Estrogens as a New Paradigm for the Treatment of Menopausal Symptoms and Osteoporosis Prevention Endocrinology, December 1, 2008; 149(12): 6084 - 6091. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Ix, M. A. Allison, J. O. Denenberg, M. Cushman, and M. H. Criqui Novel cardiovascular risk factors do not completely explain the higher prevalence of peripheral arterial disease among African Americans. The San Diego Population Study. J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2347 - 2354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Ganotakis, I. F. Gazi, J. A. Papadakis, I. A. Jagroop, D. R. Nair, and D. P. Mikhailidis The Relationship Between Circulating Fibrinogen and Lipoprotein (a) Levels in Patients With Primary Dyslipidemia Clinical and Applied Thrombosis/Hemostasis, January 1, 2007; 13(1): 35 - 42. [Abstract] [PDF]
|
|
|
|
 |
|
 V. L. Ballard and J. M. Edelberg Harnessing Hormonal Signaling for Cardioprotection Sci. Aging Knowl. Environ., December 21, 2005; 2005(51): re6 - re6. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Newton, A. Z. LaCroix, S. R. Heckbert, L. Abraham, D. McCulloch, and W. Barlow Estrogen Therapy and Risk of Cardiovascular Events Among Women With Type 2 Diabetes Diabetes Care, October 1, 2003; 26(10): 2810 - 2816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E Roeters van Lennep, H.T. Westerveld, D.W. Erkelens, and E. E van der Wall Risk factors for coronary heart disease: implications of gender Cardiovasc Res, February 15, 2002; 53(3): 538 - 549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. S Mikkola and T. B Clarkson Estrogen replacement therapy, atherosclerosis, and vascular function Cardiovasc Res, February 15, 2002; 53(3): 605 - 619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hirata, K. Shimada, H. Watanabe, T. Muro, M. Yoshiyama, K. Takeuchi, T. Hozumi, and J. Yoshikawa Modulation of coronary flow velocity reserve by gender, menstrual cycle and hormone replacement therapy J. Am. Coll. Cardiol., December 1, 2001; 38(7): 1879 - 1884. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhang, J.-J. Jiao, B. R. Bhavnani, and S.-P. Tam Regulation of human apolipoprotein A-I gene expression by equine estrogens J. Lipid Res., November 1, 2001; 42(11): 1789 - 1800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Mosca, P. Collins, D. M. Herrington, M. E. Mendelsohn, R. C. Pasternak, R. M. Robertson, K. Schenck-Gustafsson, S. C. Smith Jr, K. A. Taubert, and N. K. Wenger Hormone Replacement Therapy and Cardiovascular Disease: A Statement for Healthcare Professionals From the American Heart Association Circulation, July 24, 2001; 104(4): 499 - 503. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Ricci, G. Tamaro, R. Simeone, E. Giolo, G. Nucera, F. De Seta, and S. Guaschino Lipoprotein(a) changes during natural menstrual cycle and ovarian stimulation with recombinant and highly purified urinary FSH Hum. Reprod., March 1, 2001; 16(3): 449 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Bittner Estrogens, lipids and cardiovascular disease: no easy answers J. Am. Coll. Cardiol., February 1, 2001; 37(2): 431 - 433. [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Park, H. H. Jung, W. S. Yang, S. B. Kim, W. K. Min, and H. S. Chi Effects of hormonal replacement therapy on lipid and haemostatic factors in post-menopausal ESRD patients Nephrol. Dial. Transplant., November 1, 2000; 15(11): 1835 - 1840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Mosca The Role of Hormone Replacement Therapy in the Prevention of Postmenopausal Heart Disease Arch Intern Med, August 14, 2000; 160(15): 2263 - 2272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Shlipak, J. A. Simon, E. Vittinghoff, F. Lin, E. Barrett-Connor, R. H. Knopp, R. I. Levy, and S. B. Hulley Estrogen and Progestin, Lipoprotein(a), and the Risk of Recurrent Coronary Heart Disease Events After Menopause JAMA, April 12, 2000; 283(14): 1845 - 1852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Mooser, M. M. Berger, L. Tappy, C. Cayeux, S. M. Marcovina, R. Darioli, P. Nicod, and R. Chiolero Major Reduction in Plasma Lp(a) Levels During Sepsis and Burns Arterioscler Thromb Vasc Biol, April 1, 2000; 20(4): 1137 - 1142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nishino, M. J. Malloy, J. Naya-Vigne, J. Russell, J. P. Kane, and R. F. Redberg Lack of association of lipoprotein(a) levels with coronary calcium deposits in asymptomatic postmenopausal women J. Am. Coll. Cardiol., February 1, 2000; 35(2): 314 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhu, B. Bonet, H. Gillenwater, and R. H. Knopp Opposing Effects of Estrogen and Progestins on LDL Oxidation and Vascular Wall Cytotoxicity: Implications for Atherogenesis Experimental Biology and Medicine, December 1, 1999; 222(3): 214 - 221. [Abstract] [Full Text]
|
|
|
|
|
|
K. K. Koh, A. Blum, L. Hathaway, R. Mincemoyer, G. Csako, M. A. Waclawiw, J. A. Panza, and R. O. Cannon III Vascular Effects of Estrogen and Vitamin E Therapies in Postmenopausal Women Circulation, November 2, 1999; 100(18): 1851 - 1857. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Markowska Sex Dimorphisms in the Rate of Age-Related Decline in Spatial Memory: Relevance to Alterations in the Estrous Cycle J. Neurosci., September 15, 1999; 19(18): 8122 - 8133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Harjai Potential New Cardiovascular Risk Factors: Left Ventricular Hypertrophy, Homocysteine, Lipoprotein(a), Triglycerides, Oxidative Stress, and Fibrinogen Ann Intern Med, September 7, 1999; 131(5): 376 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cushman, C. Legault, E. Barrett-Connor, M. L. Stefanick, C. Kessler, H. L. Judd, P. A. Sakkinen, and R. P. Tracy Effect of Postmenopausal Hormones on Inflammation-Sensitive Proteins : The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study Circulation, August 17, 1999; 100(7): 717 - 722. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. F. Col, S. G. Pauker, R. J. Goldberg, M. H. Eckman, R. K. Orr, E. M. Ross, and J. B. Wong Individualizing Therapy to Prevent Long-term Consequences of Estrogen Deficiency in Postmenopausal Women Arch Intern Med, July 12, 1999; 159(13): 1458 - 1466. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Acquati, R. Hammer, B. Ercoli, V. Mooser, R. Tao, V. Rönicke, A. Michalich, G. Chiesa, R. Taramelli, H. H. Hobbs, et al. Transgenic mice expressing a human apolipoprotein[a] allele J. Lipid Res., June 1, 1999; 40(6): 994 - 1006. [Abstract] [Full Text]
|
|
|
|
 |
|
 Hormone Replacement Therapy Lowers Lipoprotein(a) Journal Watch (General), March 27, 1998; 1998(327): 2 - 2. [Full Text]
|
|